EGFR (N771_P772insH)

EGFR · Variant type: indel · HGVS: p.N771_P772insH

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Canertinib	99.9%	0.1%	96.49
2	Pralsetinib	99.9%	0.1%	93.43
3	Mobocertinib	99.5%	0.5%	97.22
4	Lazertinib	99.2%	0.8%	97.47
5	Neratinib	99.1%	0.9%	93.18
6	Erlotinib	98.4%	1.6%	99.75
7	Vandetanib	98.3%	1.7%	95.74
8	Alpelisib	87.5%	12.5%	97.22
9	Pacritinib	84.7%	15.3%	88.64
10	Gilteritinib	70.7%	29.4%	88.97
11	Zanubrutinib	44.1%	55.9%	98.24
12	Pemigatinib	43.8%	56.2%	98.23
13	Defactinib	38.5%	61.5%	92.68
14	Pirtobrutinib	31.3%	68.7%	99.49
15	Fedratinib	26.1%	73.9%	96.21
16	Avapritinib	20.3%	79.7%	97.73
17	Tenalisib	17.6%	82.4%	97.98
18	Repotrectinib	17.6%	82.4%	84.21
19	Pexidartinib	14.8%	85.2%	99.49
20	Entrectinib	12.6%	87.4%	93.69
21	Tucatinib	11.9%	88.1%	99.75
22	Darovasertib	11.5%	88.5%	96.99
23	Capmatinib	10.2%	89.8%	99.75
24	Quizartinib	8.9%	91.1%	99.50
25	Upadacitinib	8.0%	92.0%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Canertinib	99.9%	98.4%	+1.5%
Pralsetinib	99.9%	99.1%	+0.8%
Mobocertinib	99.5%	100.0%	-0.5%
Lazertinib	99.2%	100.0%	-0.8%
Neratinib	99.1%	100.0%	-0.9%
Erlotinib	98.4%	99.4%	-1.0%
Vandetanib	98.3%	99.3%	-1.0%
Alpelisib	87.5%	—	—
Pacritinib	84.7%	—	—
Gilteritinib	70.7%	91.0%	-20.4%
Zanubrutinib	44.1%	88.2%	-44.1%
Pemigatinib	43.8%	—	—
Defactinib	38.5%	94.6%	-56.1%
Pirtobrutinib	31.3%	—	—
Fedratinib	26.1%	—	—
Avapritinib	20.3%	—	—
Tenalisib	17.6%	—	—
Repotrectinib	17.6%	—	—
Pexidartinib	14.8%	—	—
Entrectinib	12.6%	—	—
Tucatinib	11.9%	—	—
Darovasertib	11.5%	—	—
Capmatinib	10.2%	—	—
Quizartinib	8.9%	—	—
Upadacitinib	8.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.7ms